Treatment options for recurrent giant cell tumors of bone

Balke, Maurice; Ahrens, H.; Streitbuerger, Arne; Koehler, Gabriele; Winkelmann, Winfried; Gosheger, Georg; Hardes, Jendrik

doi:10.1007/s00432-008-0427-x

Cited by 95 publications

(111 citation statements)

References 43 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the larger study, Balke et al 20 and Becker et al 21 mentioned that the importance of combination treatment of thorough curettage with adjuvant treatments such as high-speed burr, PMMA, or phenolization even when they were recurrent GCT. Balke et al 20 reported that they could reduce the re-recurrence rate from 58.8% in no adjunct group to 21.7% in all adjuncts (PMMA + burring) group.…”

Section: Discussionmentioning

confidence: 99%

“…Balke et al 20 reported that they could reduce the re-recurrence rate from 58.8% in no adjunct group to 21.7% in all adjuncts (PMMA + burring) group. In this study, second recurrence rate after recurettage with adjuvant treatment was 33.9%, it could stand comparison with other reported rate.…”

Section: Discussionmentioning

confidence: 99%

“…We also found that the significant correlation with Campanacci Grade II & III and the adjacent joint sacrifice. Balke et al 20 reported that 70% of local recurrence occurred within the first 2 years after initial treatment, and they recommended short term controls by X-ray or MRI. In this study, median interval from initial surgery to first recurrence was 16.0 months and 69% of recurrence occurred within 24 months.…”

Section: Discussionmentioning

confidence: 99%

“…The incidence of local recurrence, lung metastasis after treatment of primary GCT, and malignant transformation have been described 1,2,6,7,[13][14][15][16] . However, the clinical behavior of recurrent GCT, treatment strategy, and the factors affecting the clinical outcome has not been fully ellucidated [17][18][19][20][21][22] . In this multi-center study by the Eastern Asian Musculoskeletal Oncology Group (EAMOG), we retrospectively investigate the prognosis for 110 patients with recurrent GCT of bone in the extremities, and we examine the potential factors affecting the clinical outcome of these patients.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group

Takeuchi

Tsuchiya

Niu

et al. 2011

Journal of Orthopaedic Science

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group

Takeuchi

Tsuchiya

Niu

et al. 2011

Journal of Orthopaedic Science

View full text Add to dashboard Cite

“…It is the least invasive surgical option and usually provides the possibility to save the joint adjacent to the tumor. Intralesional curettage may be combined with the use of local adjuncts, such as PMMA void filling [1,3,4,15,20,33,37,42,45], hydrogen peroxide [3,4], phenol [15,37,39,40,42], and cryotherapy [24,26,27] with the intention to further reduce the risk of local recurrence.…”

Section: Introductionmentioning

confidence: 99%

Recurrent Giant Cell Tumor of Long Bones: Analysis of Surgical Management

Klenke

Wenger

Inwards

et al. 2011

Clinical Orthopaedics &Amp; Related Research

112

104

View full text Add to dashboard Cite

Background Treatment of giant cell tumor of bone (GCT) often is complicated by local recurrence. Intralesional curettage is the standard of care for primary GCTs. However, there is controversy whether intralesional curettage should be preferred over wide resection in recurrent GCTs. Questions/purposes We investigated the rerecurrencefree survival after surgical treatment of recurrent GCTs to determine the influence of the surgical approach, adjuvant treatment, local tumor presentation, and demographic factors on the risk of further recurrence. Patients and Methods We retrospectively reviewed the medical records of 46 patients with recurrent GCTs of long bones treated with wide resection or intralesional curettage and compared these cohorts. Recurrence rates, risk factors for recurrence, and the development of pulmonary metastases were determined. The minimum followup was 37 months (mean, 134 months; range, 37-337 months).

show abstract

Transcriptomic and proteomic analyses in bone tumor cells: Deciphering parathyroid hormone-related protein regulation of the cell cycle and apoptosis

Mak

Turcotte

Ghert

2012

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Giant cell tumor of bone (GCT) is an aggressive skeletal tumor characterized by local bone destruction, high recurrence rates, and metastatic potential. Previous works in our laboratory, including functional assays, have shown that neutralization of parathyroid hormone-related protein (PTHrP) in the cell environment inhibits cell proliferation and induces cell death in GCT stromal cells, indicating a role for PTHrP in cell propagation and survival. The objective of this study was to investigate the global gene and protein expression patterns of GCT cells in order to identify the underlying pathways and mechanisms of neoplastic proliferation provided by PTHrP in the bone microenvironment. Primary stromal cell cultures from 10 patients with GCT were used in this study. Cells were exposed to optimized concentrations of either PTHrP peptide or anti-PTHrP neutralizing antiserum and were analyzed with both cDNA microarray and proteomic microarray assays in triplicate. Hierarchical clustering and principal component analyses confirmed that counteraction of PTHrP in GCT stromal cells results in a clear-cut gene expression pattern distinct from all other treatment groups and the control cell line human fetal osteoblast (hFOB). Multiple bioinformatics tools were used to analyze changes in gene/protein expression and identify important gene ontologies and pathways common to this anti-PTHrP-induced regulatory gene network. PTHrP neutralization interferes with multiple cell survival and apoptosis signaling pathways by triggering both death receptors and cell cycle-mediated apoptosis, particularly via the caspase pathway, TRAIL pathway, JAK-STAT signaling pathway, and cyclin E/CDK2-associated G1/S cell cycle progression. These findings indicate that PTHrP neutralization exhibits anticancer potential by regulating cell-cycle progression and apoptosis in bone tumor cells, with the corollary being that PTHrP is a pro-neoplastic factor that can be targeted in the treatment of bone tumors. ß

show abstract

Treatment options for recurrent giant cell tumors of bone

Cited by 95 publications

References 43 publications

The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group

The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group

Recurrent Giant Cell Tumor of Long Bones: Analysis of Surgical Management

Transcriptomic and proteomic analyses in bone tumor cells: Deciphering parathyroid hormone-related protein regulation of the cell cycle and apoptosis

Contact Info

Product

Resources

About